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We examined the association between C-reactive protein
(CRP) and short- and long-term adverse outcomes in
peritoneal dialysis (PD)-associated peritonitis. Serum CRP
levels were measured at baseline and 3 weeks after initiation
of treatment in 209 patients with an incident episode of
peritonitis between 1 January 1999 and 31 March 2005.
Patients were followed until 31 May 2005. Short-term adverse
outcomes included switch to hemodialysis, death, persistent
infection beyond planned therapy duration, and relapse;
long-term adverse outcomes included a subsequent
peritonitis event or death. After adjustment for age, gender,
diabetes, duration of renal replacement therapy and
causative organism, patients with higher CRP levels at
diagnosis had a greater odds of an adverse short-term
outcome (odds ratio 1.57 (95% confidence interval (CI):
0.61–4.02), 2.73 (95% CI: 1.09–6.87), and 3.38 (95% CI:
1.36–8.42) in the second, third, and highest quartiles). In
patients who met criteria for resolution of peritonitis 3 weeks
after diagnosis, those with higher CRP levels had a greater
risk of a long-term adverse outcome (hazard ratio 1.79 (95%
CI: 1.05–3.07)). In conclusion, higher levels of CRP are
independently associated with adverse outcomes in
PD-associated peritonitis. Serial measurement of this
marker during the course of peritonitis may facilitate
earlier identification of individuals at greater risk of
complications.
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Peritonitis is an important cause of morbidity, mortality and
technique failure in peritoneal dialysis (PD) patients.1
Patients generally remain ambulatory during the treatment
of peritonitis and contact with medical personnel may be
relatively infrequent. For these reasons, easily obtainable
predictors of short- and long-term outcomes would be
clinically useful. Previous studies have identified several
factors associated with adverse outcomes from peritonitis,
including causative organism, duration of dialysis, and
prolonged elevation of PD fluid white blood cell count
(WCC) after initiation of antibiotic treatment.2,3 However,
neither causative organism nor persistence of elevated PD
fluid WCC is available at the time of diagnosis. Furthermore,
many patients have culture negative infections.
C-reactive protein (CRP) is a marker of inflammation,
and elevated serum levels have been associated with an
increased risk of cardiovascular events and mortality in
the general population as well as in patients with
kidney disease.4–12 The potential utility of serial CRP
measurements in predicting outcomes from PD-associated
peritonitis was initially reported in a series of 39 consecutive
patients.13 In this study, the magnitude of the CRP response
correlated with the severity of the episode, patients who
resolved with antibiotics showed a prompt fall in CRP
towards normal, and patients in whom the serum CRP
value remained raised had a complicated course; however, the
association between CRP and hard end points, such as
mortality and recurrent peritonitis events, has not been
examined.
The purpose of this prospective cohort study was to
examine the association between CRP levels and outcomes
from PD-associated peritonitis in patients presenting with an
incident episode of peritonitis. Specifically, our objectives
were (1) to determine if CRP level at the time of diagnosis is
associated with an increased risk of adverse outcomes in the
short term, including switch to hemodialysis owing to
peritonitis, death during the course of treatment, persistent
infection after completion of intended antibiotic treatment,
or relapse of peritonitis; and (2) in the subgroup of patients
whose peritonitis is clinically resolved 3 weeks following
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initiation of treatment, to determine whether CRP level is
associated with an increased risk of long-term adverse
outcomes, including development of a subsequent peritonitis
event or death from any cause.
RESULTS
Study patient characteristics
During the study period, 228 PD patients had an incident
episode of peritonitis; 19 patients with missing data for the
baseline CRP level were excluded. Demographic character-
istics of the 209 included patients and the organisms cultured
from the dialysate at presentation are shown in Table 1. The
majority of infections were caused by Gram-positive organ-
isms (53.1%), followed by Gram-negative organisms
(19.6%), and culture negative infections (17.2%). In all,
10% of patients grew more than one organism from the
initial PD fluid specimen. Patients with missing baseline CRP
values had similar demographic characteristics to the
remaining subjects (data not shown).
Baseline CRP level and short-term adverse outcomes
At baseline, the median CRP value was 56.0 mg/l (25–75th
percentile: 22.0–126.0 mg/l). CRP in quartile 1 was
p22.0 mg/l, in quartile 2 was 22.1–56.0 mg/l, in quartile 3
was 56.1–126.0 mg/l, and in quartile 4 was X126.1 mg/l.
Short-term adverse outcomes were observed in 72
of 209 (34.0%) patients with a median time to event of
18 days (25–75th percentile: 6–30 days). Thirty-three patients
(15.8%) were switched to hemodialysis, at least temporarily;
three of these required a laparotomy for bowel
wall perforation (N¼ 2) or diverticular abscess (N¼ 1).
Eleven (5.3%) patients died during the course of treatment;
three of these had intra-abdominal pathology identified
before death (one of each of: bowel wall perforation, gall
bladder sepsis, and ischemic bowel). Ten patients (4.8%)
demonstrated cytological or culture evidence of persistent
infection at week 3, resulting in an extension of antibiotic
treatment. Eighteen patients (8.6%) experienced a relapse
within 4 weeks of cessation of antibiotic treatment.
Of the 18 patients who relapsed, the initial peritonitis
event was caused by Gram-positive organisms other
than Staphylococcus aureus in eight (44%) patients, poly-
microbial infections in four (22%) patients, culture negative
infections in three (17%) patients, Staphylococcus aureus in
two (11%) patients, and a Gram-negative organism in one
(6%) patient.
In the univariate logistic regression analysis, the odds ratio
(OR) for developing a short-term adverse outcome from
peritonitis increased progressively with each quartile of CRP.
Compared to the reference group (quartile 1), the OR was
1.90 for quartile 2 (95% CI: 0.75–4.59), 3.01 for quartile 3
(95% CI: 1.24–7.30), and 3.98 (95% CI: 1.66–9.57) for
quartile 4. After adjustment for age, gender, diabetes,
duration of renal replacement therapy (RRT), and causative
organism in the multivariable model, the upper two quartiles
of CRP (third quartile: OR 2.73 (95% CI: 1.09–6.87); highest
quartile: OR 3.38 (95% CI: 1.36–8.42) compared to quartile
1) and causative organism (OR 2.76 (95% CI 1.48–5.12) for
Staphylococcus aureus, Gram negatives and polymicrobial
infections compared to others) were statistically significantly
associated with an increased risk of short-term adverse
outcomes. Adjustment for duration of PD in place of
duration of RRT did not alter the results. The results of the
multivariable model are shown in Table 2.
CRP level at week 3 and long-term adverse outcomes
Three weeks following initiation of antibiotic treatment, 155
of 209 patients met the criteria for resolution of peritonitis.
Of these 155 patients, 122 had CRP measurements available
Table 1 | Baseline demographic characteristics of the study
population
Incident patients
N=209
Age (year) (mean7s.d.) 58.9716.9
Male (n, %) 123 (58.9)
Cause of ESRD (n, %)
Diabetes 40 (19.1)
Glomerulonephritis 41 (19.6)
Other 128 (61.2)
Diabetes (n, %) 65 (31.1)
Cardiovascular disease (n, %) 95 (45.5)
Duration of RRT (year) (median, 25–75th percentile) 1.0 (0.3–2.3)
Duration of PD (year) (median, 25–75th percentile) 0.8 (0.2–1.6)
PD system (n, %)
CAPD 162 (77.5)
APD 47 (22.5)
Baseline (mean7s.d.)
Hemoglobin (g/dl) 10.671.8
White blood cell count 11.275.3
Albumin (g/l) 32.475.7
Fluid culture at baseline
Gram positive (n, %) 111 (53.1)
Coagulase-negative Staphylococcus 70
Staphylococcus aureus 18
Streptococcus species 16
Diphtheroids 4
Enterococcus 3
Gram negative 41 (19.6)
‘Coliforms’ 3
Escherichia coli 17
Klebsiella 6
Pseudomonas 6
Enterobacter 2
Acintetobacter 2
Bacteroides 2
Prevotella 1
Pasteurella 1
Neisseria 1
Culture negative 36 (17.2)
Polymicrobial 21 (10.0)
ESRD, end-stage renal disease; PD, peritoneal dialysis; RRT, renal replacement
therapy; s.d., standard deviation.
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at this time. The median CRP value reported at week 3 was
8.4 mg/l (25–75th percentile: 8.0–23.0 mg/l). Eighty-six of 122
(70.5%) patients experienced a long-term adverse outcome
(11 deaths and 75 peritonitis episodes) at a median time of
221 days. The median time to development of long-term
adverse outcomes (254 days) and the proportion of patients
experiencing an adverse event (69.7%) was similar in the 33
patients with missing values for CRP at week 3.
The Kaplan–Meier survival curves for the development of
a subsequent peritonitis event or death from any cause are
shown in Figure 1. The time to occurrence of these long-term
outcomes was statistically significantly shorter at 147 days in
the group with week 3 CRP values in the highest quartile
(423.0 mg/l), compared to 291 days in those with CRP
p23.0 mg/l (log rank P¼ 0.03). Of the 30 patients with CRP
423 mg/l at 3 weeks, 17 (57%) had peritonitis caused by
Gram-positive organisms other than Staphylococcus aureus,
ten (33%) were caused by Staphylococcus aureus, polymicro-
bial or Gram-negative organisms, and four (13%) were
culture negative.
In the univariate Cox regression analysis, the hazard ratio
(HR) for adverse long-term outcomes was 1.71 (95% CI:
1.04–2.82) for patients in the highest quartile of CRP
compared to those with lower values. Results of the
multivariable Cox model are shown in Table 3. In the
adjusted analysis, the HR for long-term adverse outcomes
was 1.79 (95% CI: 1.05–3.07) for patients in the highest
quartile of CRP compared to the remaining patients. Men
were also at statistically increased risk of developing long-
term adverse outcomes, with a HR of 1.82 (95% CI:
1.13–2.94) compared to women. Additional adjustment for
baseline CRP level did not significantly alter the results of the
multivariable model, nor did adjustment for duration of PD
in place of duration of RRT.
DISCUSSION
In this prospective cohort study of PD patients presenting
with an incident episode of peritonitis, we found that higher
baseline levels of serum CRP were associated with an
increased risk of short-term adverse outcomes including
death, switch to hemodialysis, persistent infection, and
relapse of peritonitis. In patients who met clinical and
laboratory criteria for resolution of peritonitis 3 weeks after
beginning antibiotic treatment, higher CRP levels were
associated with an increased risk of long-term adverse events,
including a subsequent peritonitis episode or death from any
cause. These associations persisted after adjustment for
potential confounders, including causative organism. A
Table 2 | Multivariable model for development of short-term
adverse outcomes (switch to hemodialysis, death, persistent
infection, and relapse) in PD-associated peritonitis
Variable OR 95% CI P-value
CRP quartile
1 (o22 mg/l) 1.0
2 (24–56 mg/l) 1.57 0.61–4.02 0.35
3 (57–126 mg/l) 2.73 1.09–6.87 0.03
4 (127–288 mg/l) 3.38 1.36–8.42 0.001
Organism
Non-S. aureus Gram-positive cocci
and culture negative
1.0
S. aureus, Gram negative,
Polymicrobial
2.76 1.48–5.12 0.001
Male gender 0.87 0.46–1.62 0.65
Diabetes 1.22 0.63–2.37 0.56
Age (per year increase) 1.02 1.00–1.03 0.12
Duration of RRT (per year increase) 1.03 0.97–1.10 0.31
CI, confidence interval; CRP, C-reactive protein; OR, odds ratio; PD, peritoneal
dialysis; RRT, renal replacement therapy.
0 200 400 600 800 1000
Time (days)
0.0
0.2
0.4
0.6
0.8
1.0
Pr
op
or
tio
n 
fre
e 
of
 p
er
ito
ni
tis
 o
r d
ea
th
Week 3 CRP  23 mg/l
Week 3 CRP > 23 mg/l
Week 3 CRP  23 mg/l
Week 3 CRP > 23mg/l
No. at risk 
92 44 24 14 8 3 
30  5  3  2 1 1
Figure 1 | Time to next peritonitis event or death from any cause.
Patients who show resolution of peritonitis at 3 weeks following
initiation of antibiotic treatment are stratified by CRP level. Log-rank
P¼ 0.03. The number of remaining patients at risk in each group is
shown below the figure.
Table 3 | Multivariable Cox regression model for
development of long-term adverse outcomes (subsequent
peritonitis event or death from any cause) in patients who
demonstrated resolution of peritonitis three weeks after
initiation of antibiotic therapy
Variable HR 95% CI P-value
CRP category
1 (p23 mg/l) 1.0
2 (423 mg/l) 1.79 1.05–3.07 0.03
Organism
Non-S. aureus gram- 1.0
positive cocci and
Culture negative
S. aureus, gram negative,
polymicrobial
1.43 0.89–2.29 0.14
Male gender 1.82 1.13–2.94 0.01
Diabetes 1.12 0.70–1.79 0.63
Age455 years 1.57 0.92–2.69 0.10
Duration of RRT (per year increase) 0.95 0.89–1.01 0.11
CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; RRT, renal
replacement therapy.
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predictor of outcome from peritonitis that is easily measured
at the time of presentation and routine follow-up is of
particular relevance to this group of ambulatory patients who
may reside in areas remote from immediate medical
attention.
CRP levels are known to increase with declining kidney
function.5 However, the degree of CRP elevation at diagnosis
was quite marked in our study, and was many times greater
than those reported in ‘stable’ (noninfected) PD patients,
where median levels ranging from 3 to 15 mg/l have been
reported.9,11,12,14 Troidle et al.14 also observed marked
elevations of CRP during PD-associated peritonitis. In their
study, the mean level of CRP was 118.3 mg/l 48 h after
diagnosis. These levels likely reflect the intensity of the
inflammatory response and are consistent with the role of
CRP in nonspecific immunity as an activator of the
complement cascade. As CRP level is associated with an
increased risk of short-term adverse outcomes from perito-
nitis, the degree of CRP elevation is presumably also an
indicator of a more severe infection.
By 3 weeks, more than half of our patients had CRP levels
in the range reported as ‘baseline’ levels in other studies of
PD patients. As pre-peritonitis CRP levels were not available
in all of our patients, we are unable to comment on how
many of them had persistent elevations of CRP above their
individual baseline levels at this time. Nonetheless, patients
with the highest CRP levels at 3 weeks experienced an
increased risk of long-term adverse events, which included a
combination of a subsequent peritonitis episode or death.
The association between elevated levels of CRP and mortality
in PD patients has been described in other studies.9,11 This
may be related to the potential role of inflammation in
atherogenesis and development of cardiovascular disease.15
Our sample size was not large enough to demonstrate a
statistically significant association between elevated CRP and
increased risk of future peritonitis events alone (when
censored for death, the HR for development of a subsequent
peritonitis event was 1.31 (95% CI 0.61–2.81) for patients in
the group with CRP 423 mg/l compared to patients with
CRP p23 mg/l at 3 weeks). Nonetheless, the potential
association between elevated CRP and increased risk of
future peritonitis events is novel and likely reflects a distinct
pathophysiology. For example, persistent elevations of CRP
immediately following peritonitis treatment may signal
ongoing subclinical infection at the PD catheter exit site or
tunnel, which serves as the bacterial source for future
infections.
Despite the frequent occurrence of PD-associated perito-
nitis, it remains difficult to predict which patients will have
poor outcomes. Our study is consistent with others that have
demonstrated that causative organism (Gram negative, S.
aureus and polymicrobial infections in particular) is an
important predictor of outcome.2,3,16–18 However, few studies
have examined the predictive utility of specific host factors.
Krishnan et al.2 studied 399 episodes of peritonitis in 191
individuals and found that the duration of PD and the
number of days the PD effluent cell count was 4100/ml were
independently predictive of nonresolution (death, catheter
removal, or transfer to hemodialysis). Duration of dialysis
was not predictive of outcomes in our study; we were not
able to adjust for the duration of PD effluent cell count
4100/ml as this information was not available in all patients.
Also in contrast to our study, Choi et al.19 found that older
patients and those with a longer duration of PD were at
increased risk for catheter removal in a retrospective study of
64 peritonitis episodes. In one retrospective study of 693
episodes of peritonitis, elevated CRP was associated with
greater peritonitis-related mortality; however, only 41 events
were available for inclusion in the multivariable model.3 Our
study is unique in its examination of both short- and long-
term outcomes following peritonitis, thus expanding the
sparse existing literature on this subject.
The strengths of this study are its prospective design,
rigorous follow-up, and large size. In addition, the demo-
graphic characteristics of our patient population and the
distribution of organisms causing peritonitis are typical of
those previously reported, supporting the generalizability of
our findings to PD patients elsewhere. However, our findings
must be interpreted within the limitations of the study
design. This was an observational study, and our results may
partially reflect residual confounding by unmeasured factors.
For example, data was not uniformly available on indicators
of disease severity, such as hypotension at diagnosis or
admission to an intensive care unit. The CRP assays in this
study were not performed at a central laboratory, potentially
introducing bias related to interlaboratory variability of
measurements. As the CRP elevations observed were quite
marked, it is less likely that small differences that may exist
between the assays played a large role in biasing our results.
In addition, all assays were calibrated according to interna-
tional standards and adjustment of the multivariable analyses
for site of CRP measurement did not significantly alter our
results. Finally, the CRP assays used were not the highly
sensitive type. However, the degree of CRP elevation
associated with adverse outcomes following PD-associated
peritonitis did not require a highly sensitive assay for
detection. Furthermore, the assays used would be expected
to produce similar results to a highly sensitive assay within
the range of values observed in our study.
We used duration of RRT as a proxy for residual renal
function in our analyses. Similar methods were used by
Krishnan et al.,2 where duration of PD was entered into the
multivariable model. When we investigated the effect of
residual renal function in patients with available data
(N¼ 143), it was not associated with either short- or long-
term adverse outcomes in univariate analyses. One possible
explanation for this lack of statistical association is that
residual renal function measurements were taken at variable
time intervals before the onset of peritonitis (as the timing of
infection was unpredictable) and, as a result, may not have
reflected the true residual renal function at the time of
infection.
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In conclusion, in patients presenting with an episode of
PD-associated peritonitis, a higher level of CRP is indepen-
dently associated with an increased risk of short- and long-
term adverse outcomes. This result identifies a potential role
for serial measurement of this inflammatory marker during
the course of antibiotic treatment to identify patients at
greater risk of treatment failure. Our study suggests that those
with a CRP level 457 mg/l at diagnosis may be at particular
risk. However, whether patients with the most marked
elevations of CRP would benefit from a more aggressive
strategy of investigation, monitoring, and treatment of PD-
associated peritonitis requires further study.
MATERIALS AND METHODS
Subjects
This was a prospective cohort study of 209 patients on continuous
PD followed at the Oxford Kidney Unit (United Kingdom) and its
satellite facilities (Milton Keynes and High Wycombe Renal Units)
who presented with an incident episode of PD-associated peritonitis
between 1 January 1999 and 31 March 2005. The incident episode of
peritonitis was defined as the first episode of peritonitis experienced
by the patient since the initiation of PD. All patients had double cuff
silastic PD catheters placed using sterile surgical technique.
Demographic and clinical characteristics were determined at the
time of PD initiation. End-stage renal disease was classified as
follows: diabetes mellitus (type 1 or 2), glomerulonephritis, or other
causes. Patients were recorded as having cardiovascular disease if
they had a history of cerebrovascular disease, ischemic heart disease,
congestive heart failure, or peripheral vascular disease.
Diagnosis of peritonitis
Criteria for the diagnosis of peritonitis were: cloudy dialysate and an
elevated dialysate WCC of more than 100/mm3, in accordance with
published guidelines from the International Society of Peritoneal
Dialysis.20 In cases where fluid WCC was unavailable, cloudy fluid
and/or abdominal pain accompanied by a positive fluid culture was
considered diagnostic (N¼ 5).
Treatment and follow-up
All patients were assessed by PD unit/renal ward nurses and
reviewed by a physician at diagnosis. Empiric treatment consisted of
intraperitoneal vancomycin (single dose of 1.5 g in patients o60 kg;
2 g in patients 460 kg) and oral ciprofloxacin (initial dose 1 g,
followed by 500 mg twice daily). Antibiotic treatment was subse-
quently tailored once antimicrobial sensitivities were available. The
standard duration of antibiotic treatment was 2 weeks. Treatment
for longer than 2 weeks was left to the discretion of the physician.
Routine follow-up visits were scheduled at 1 and 3 weeks following
initiation of treatment. PD catheters were removed and patients
were switched to hemodialysis if they demonstrated a lack of
improvement within the first week of appropriate antibiotic therapy,
if peritoneal dialysate specimens grew yeast species at any time
during follow-up, if a clinically apparent tunnel infection was
present at diagnosis, and/or if a laparotomy was required for intra-
abdominal pathology (e.g. bowel perforation).
Laboratory measurements
PD fluid was sent for Gram stain, cell count, culture and sensitivity
at the time of presentation, and then at 1 and 3 weeks following
initiation of antibiotic treatment. Blood samples were sent for CRP
levels at baseline (within 48 h of diagnosis) and 3 weeks (range:
17–25 days) following initiation of antibiotic treatment. CRP levels
were determined by immunoturbidimetry at three institutions. In
Oxford, reagents were supplied by Abbott Laboratories (Abbott
Park, IL, USA) and the lower reporting limit was 8 mg/l; in Milton
Keyes and High Wycombe, reagents were supplied by Beckman
Coulter Inc. (Fullerton, CA, USA) and the lower reporting limit was
5 mg/l. Assays were calibrated according to National and Interna-
tional Federation of Clinical Chemistry (IFCC) guidelines. The
coefficients of variation wereo5% for both assays. Other laboratory
investigations, such as complete blood counts and serum chemistry,
were performed at the discretion of the treating physician.
Definitions of outcome variables
Peritonitis was defined as resolved if the PD fluid WCC was o100/
mm3, PD fluid cultures were negative and/or patients experienced a
clinical resolution at completion of the intended course of antibiotic
treatment.
Short-term adverse outcomes included death during the course
of peritonitis treatment, switch to hemodialysis during the course of
peritonitis treatment, persistent infection (failure to achieve
cytological and/or culture remission after the intended duration of
antibiotic treatment), and relapse (any PD fluid with WCC
4100 mm3 within 4 weeks of cessation of antibiotic therapy,
regardless of whether or not PD fluid culture results were positive).
Patients with resolved peritonitis at 3 weeks were followed for the
development of the following long-term outcomes of interest:
peritonitis occurring any time after cessation of antibiotic therapy
and death from any cause.
Statistical analysis
Baseline characteristics were summarized as mean (71 s.d.), median
(25–75th percentile), or proportions (percent), as appropriate.
Baseline CRP and short-term outcomes. Baseline CRP mea-
surements were divided into quartiles, from the lowest to the highest
levels. Logistic regression analysis was used to determine the
association between baseline CRP and short-term adverse outcomes.
A multivariable logistic regression model was used to adjust for the
following potential confounders, determined a priori: age, gender,
diabetes, duration of RRT, and causative organism (Group 1:
Culture negative infections and non-Staphylococcus aureus Gram-
positive infections; Group 2: Staphylococcus aureus, Gram negative
and polymicrobial infections). Complete data was available on all of
these covariates.
Week 3 CRP and long-term outcomes. Week 3 CRP levels were
initially divided into quartiles and the association between CRP level
and development of the long-term adverse outcomes of interest
(death from any cause, subsequent peritonitis event) was explored
using the Kaplan–Meier method. Because patients in the lower three
quartiles of CRP had a similar time to event, they were grouped
together and compared to those in the highest quartile of CRP using
the log-rank test. Cox regression analysis was used to determine the
HR for long-term adverse outcomes, comparing the highest quartile
of CRP levels to the remaining patients, adjusting for age, gender,
diabetes, duration of RRT, and causative organism. Patients were
censored at the time of transplantation, switch to hemodialysis for
reasons other than peritonitis, transfer of care out of the region, and
end of follow-up. The proportional hazards assumption was tested
using log-negative-log plots and time-dependent covariates in the
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Cox model. When age was entered into the model as a continuous
variable, the proportional hazards assumption was violated, thus, a
binary variable was created for age (p55 versus 455 years old),
which met the proportional hazards assumption.
All P-values are two-tailed and P-values o0.05 were considered
to be statistically significant. All analyses were performed with SAS
software, version 9.1 (SAS Institute, Cary, NC, USA).
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